A novel biomaging system may improve the detection of HER2-positive breast cancer, according to a paper published online in the International Journal of Cancer. Researchers at the National Institute of Standards and Technology (NIST), the National Cancer Institute (NCI), and the scientific research firm SAIC found that a chicken immunoglobulin Y (IgY) antibody created against the HER2 protein could be tagged with tiny, intense light sources known as "quantum dots" to more reliably detect the HER2 biomarker than existing diagnostic tests that use mammalian antibodies tagged with conventional fluorescent dyes. Overall, the improvement in sensitivity to the HER2 biomarker was about 40 percent to 50 percent.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 2008 - Table of Contents

DTTR April 2008 (full PDF issue)

JAMA Study Sends Chill Through IVD Market

Immucor Bets on Blood Genotyping

Third Wave Sees Clinical Revenue Grow 25% in '07

NEJM Study Probes Pharmacogenomics of Warfarin Metabolism

PerkinElmer Acquires Pediatrix’s Newborn Screening Lab

New Bioimaging System Promises Improved HER2 Testing

Ikonisys Boosts Automated FISH Platform with New Reference Lab

Quidel RSV Test Gets CLIA Waiver

Abbott to Co-Develop Pharmacogenomic Test for Lung Cancer Drug

Quest Diagnostics Signs Onto Google Health EHR

ACLA Presses SACGHS for Clarification on Genetic Testing Oversight

Beckman Coulter Launches High-Volume Testing System

IVD Stocks Fall 7%; Inverness Plummets 33%

Lung Cancer-Focused Allegro Diagnostics Raises $4 Million